Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study
Worldwide, patients with HoFH are diagnosed too late, undertreated, and at high premature ASCVD risk. Greater use of multi-LLT regimens is associated […]
Month: February 2022
Power and bullying in research
Eric Lander, director of the Office of Science and Technology Policy and science adviser to US President Joe Biden, resigned on Feb […]
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained […]
Antimicrobial resistance: time to repurpose the Global Fund
Antimicrobial resistance (AMR) is a major cause of death globally, with a burden likely to be higher than that of HIV or […]
UN sanctions hamper humanitarian work
Aid leaders have warned that unintended consequences of UN sanctions are a growing problem for humanitarian actors and have called for more […]
Diagnostics for COVID-19: moving from pandemic response to control
Diagnostics have proven to be crucial to the COVID-19 pandemic response. There are three major methods for the detection of SARS-CoV-2 infection […]
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
The most recent SARS-CoV-2 variant of concern to emerge has been named omicron.1 Its immune evasion potential was predicted by genomic data […]
The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future
The Lancet Countdown is an international collaboration that independently monitors the health consequences of a changing climate. Publishing updated, new, and improved […]
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. […]